The primary goal of this Global Alpha Emitter Market report is to maintain the record of Unusual growth strategies adopted by various companies are creating new standards for competition in the global Alpha Emitter market. Businesses around the world are aiming at increasing their profit margin and establishing a stronghold in the global market. The impact of prevailing regulatory scenario on both regional and worldwide Alpha Emitter market is provided in detail in the report.
Get Sample Copy of Alpha Emitter Market Report @ https://www.industryresearch.co/enquiry/request-sample/13999610
Key Market Trends:
Medical Application in Ovarian Cancer is Expected to Observe the Highest Growth Rate over the Forecast Period
The ovarian cancer segment in the alpha emitter market is expected to witness the highest CAGR of 35.63% during the forecast period.
The growth rate is attributed to an increasing number of new diagnosis cases. As per the estimates of the American Cancer Society, in 2018, around 22,240 women were expected to receive a new diagnosis of ovarian cancer, and about 14,070 women would die from ovarian cancer.
Ovarian cancer uses radioimmunotherapy as locally injected adjuvant therapy. Trials have evaluated the practice of complete abdominal or moving-strip external-beam radiotherapy (EBRT) or non-specific i.p. radiotherapy, with colloid preparations of Au-198 or P-32 as adjuvant therapies.
Moreover, the adoption of targeted alpha therapy with higher LET and shorter wavelengths has been promising in the treatment process. This trend is expected to gain traction in the near future.
In addition, a recent Phase I clinical trial involving At-211-MX35 F (abâ€²) showed significant efficacy, as therapeutic doses reached their targets in patients with ovarian cancer.
North America Dominates the Market and is Expected to do Same in the Forecast Period
North America currently dominates the alpha emitter market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the fact that the increase in cardiac and neurological chronic diseases is the major driving factor for the market growth in the region. For instance, 223RaCl2 (Xofigo) is the first alpha-emitting radioisotope to gain registration in the United States for palliative therapy of prostate cancer bone metastases through indirect physiological targeting.
Moreover, according to the National Cancer Institute, the number of new cases of melanoma was 21.8 per 100,000 men and women, per year. Similarly, the rising prevalence of cancer is making it imperative for the healthcare professionals across Canada to increase the radiotherapy utilization for cancer treatment. This is directly affecting the growth of the alpha emitter market in the country.
Alpha Emitter Market Covers Key Players:
Ask for Discount at https://www.industryresearch.co/enquiry/request-discount/13999610
This Report Focuses on the Alpha Emitter in the Global market, especially in North America, China, Europe, Japan, Southeast Asia, India. This report categorizes the market based on manufacturers, regions, type, and application
– The report provides a detailed analysis on current and future market trends to identify the investment opportunities
– Market forecasts till 2024, using estimated market values as the base numbers
– Key market trends across the business segments, Regions and Countries
– Key developments and strategies observed in the market
– Market Dynamics such as Drivers, Restraints, Opportunities and other trends
– In-depth company profiles of key players and upcoming prominent players
– Growth prospects among the emerging nations through 2024
– Alpha Emitter Market opportunities and recommendations for new investments
Price Of Report: $ 4250 (SUL)
Purchase Alpha Emitter Market Report @ https://www.industryresearch.co/purchase/13999610
Detailed TOC of Alpha Emitter Market Research Report 2019 – 2024:
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Awareness About the Potential Benefits of Targeted Alpha Therapy
4.2.2 Increasing Number of Patients with Cardiac and Cancer Ailments
4.3 Market Restraints
4.3.1 Short Half-life of Radiopharmaceuticals
4.3.2 Stringent Regulatory Framework and Reimbursement Issues
4.3.3 Need for High Capital Investment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Type of Radionuclide
5.1.1 Terbium (Tb-149)
5.1.2 Astatine (At-211)
5.1.3 Bismuth (Bi-212)
5.1.4 Actinium (Ac-225)
5.1.5 Radium (Ra-223)
5.1.6 Lead (Pb-212)
5.1.7 Bismuth (Bi -213)
5.2 Medical Application
5.2.3 Pancreatic Cancer
5.2.4 Ovarian Cancer
5.2.6 Bone Metastasis
5.2.8 Endocrine Tumors
5.2.9 Other Medical Applications
5.3.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.3.4 Middle East & Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East & Africa
5.3.5 South America
188.8.131.52 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Actinium Pharmaceutical Inc.
6.1.2 Alpha Tau Medical Ltd
6.1.3 Bayer AG
6.1.4 Fusion Pharmaceuticals
6.1.5 IBA Radiopharma Solutions
6.1.6 RadioMedix Inc.
6.1.7 Telix Pharmaceuticals Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
About Industry Research:
Industry Research is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market, dedicated to bringing you an ingenious concoction of data parameters.
Name: Ajay More
Organization: Industry Research
Phone: +44 20 3239 8187 / +14242530807
Email: [email protected]